Adenosine Cardioplegia; Improved Cardioprotection?

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: All

Summary

60 elective patients for CABG will be included to receive either standard hyperkalemic cardioplegia (St.Thomas Hospital Solution No I) or cardioplegia where supranormal potassium is replaced with 1.2 mM adenosine. Hypothesis as follows: 1. Adenosine instead of supranormal potassium in the cardioplegic solution give satisfactory cardiac arrest. 2. Adenosine instead of supranormal potassium in the cardioplegic solution gives equal cardioprotection. The patients will be followed with PiCCO-catheter to monitor cardiac function and repetitive blood samples to measure release of cardiac enzymes.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital of North Norway
• Treatments: Adenosine

Criteria

Inclusion Criteria:

• Elective patients

• Ejection fraction > 40%

• Age 40-75

• No release og TnT or CKMB within last week before CABG

• Pure CABG

Exclusion Criteria:

• Age >75 or < 40

• EF < 40%

• Emergency operations

• Unstable angina

• Release of TnT or CKMB within the week before operation